RSLS (Reshape Lifesciences) Quality Rank

View and export this data going back to 2021. Start your Free Trial

What is Reshape Lifesciences Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:

Interest coverage
Zscore
Debt to revenue
Equity to asset
Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:

Operating margin mean rank (10-year mean average profit margine)
Operating margin growth rank
Fscore
Predictability rank
Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
Num of year profit (number of years that is profitable within the last 10 years)
ROIC median (10-year median of ROIC)

Reshape Lifesciences Quality Rank Related Terms

Thank you for viewing the detailed overview of Reshape Lifesciences's Quality Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Reshape Lifesciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Reshape Lifesciences Inc (NAS:RSLS) » Definitions » Quality Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

18 Technology Dr., Suite 110, Irvine, CA, USA, 92618

Website

https://www.reshapelifesciences.com

Reshape Lifesciences Inc is a medical device company focused on technologies to treat obesity and metabolic diseases. The company's current portfolio includes the LAP-BAND, an Adjustable Gastric Banding System, ReShapeCare virtual health coaching program, ReShape Market Place, including ReShape Optimize a supplemental multivitamin, the Obalon Balloon System, the first and only swallowable gas-filled balloon system, and the Diabetes Bloc-Stim Neuromodulation, a technology under development as a new treatment for type 2 diabetes mellitus.

Executives

Thomas Stankovich	officer: Chief Financial Officer	1001 CALLE AMANECER, SAN CLEMENTE CA 92673
Paul F. Hickey	director, officer: President and CEO	2800 PATTON ROAD, ST. PAUL MN 55113
Barton P. Bandy	director	1001 CALLE AMANECER, SAN CLEMENTE CA 92673
Mcdougal Lori Courtney	director	2800 PATTON ROAD, ST. PAUL MN 55113
Arda Phd Minocherhomjee	director	C/O CHICAGO GROWTH PARTNERS, 303 W MADISON ST., SUITE 2500, CHICAGO IL 60606
Dan W Gladney	director	2800 PATTON ROAD, ST. PAUL MN 55113
Steven Boyd	10 percent owner	510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital, Llc	10 percent owner	510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Gary Blackford	director	7700 FRANCE AVENUE SOUTH, EDINA MN 55435
Robert J Macdonald	officer: Chief Retail Officer	C/O OBALON THERAPEUTICS INC., 5421 AVENIDA ENCINAS, SUITE F, CARLSBAD CA 92008
Daina Schmidt	officer: Vice President of Marketing	C/O OBALON THERAPEUTICS, INC., 5421 AVENIDA ENCINAS, SUITE F, SAN DIEGO CA 92008
Gilbert H Kliman	10 percent owner	C/O INTERWEST PARTNERS, 467 FIRST STREET SUITE 201, LOS ALTOS CA 94022
Arnold L Oronsky	10 percent owner	C/O INTERWEST PARTNERS, 467 FIRST STREET SUITE 201, LOS ALTOS CA 94022
Khaled Nasr	10 percent owner	467 FIRST STREET, SUITE 201, LOS ALTOS X1 94022
Interwest Partners X Lp	10 percent owner	C/O INTERWEST PARTNERS, 467 FIRST STREET SUITE 201, LOS ALTOS CA 94022